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tThe 39-member faculty for the Symposium included
eaders of the major transplantation centers from a round
he globe: France, Italy, Japan, Spain, Australia, and the
nited States. Attendees were from Belgium, Czech
epublic, France, Germany, Italy, Greece, The Nether-
ands, Poland, Switzerland, United Kingdom, Israel,
yprus, Kuwait, Saudi Arabia, United Arab Emirates,
ndia, Australia, Hong Kong, Malaysia, Singapore, Japan
orea, Taiwan, Canada, United States, Panama, Brazil,
nd Columbia.
The program was divided into 8 sessions: (1)
isk factors affecting survival in recipients of cord
lood, (2) Strategies to improve engraftment after
CBT, (3) Cord blood banking, manipulation and
nit selection, (4) Conditioning regimens, (5) Im-
une reconstitution and infections, (6) Non-hema-
opoietic stem cells, (7) The graft versus tumor
ffect, and (8) Governmental affairs. The following
omments emphasize signiﬁcant aspects of selected
resentations. Additional details are provided in the
bstracts that follow.
The Fifth Annual International Cord Blood Trans-
lantation Symposium was presented by the California
lood Bank Society and the Cord Blood Forum, and was
artially supported by unrestricted educational grants
rom StemCyte International Cord Blood Center and the
ational Marrow Donor Program (NMDP). The Sym-
osium was also partially ﬁnancially supported by a
ontract between the Health Resources and Services Ad-
inistration (HRSA), US Department of Health and
uman Services, and the California Blood Bank Society.
ny opinions, ﬁndings, conclusions or recommendations
xpressed or presented at this conference are those of the
resenters and do not necessarily reﬂect the views of the
S Government. t
380ESSION I. RISK FACTORS AFFECTING SURVIVAL IN
ECIPIENTS OF CORD BLOOD
Dr. Vanderson Rocha reviewed the risk factors af-
ecting survival after umbilical cord blood transplan-
ation (UCBT) in children and adults with hemato-
ogical malignancy. He pointed out that factors
ssociated with outcomes after allogeneic hematopoi-
tic stem cell transplantation (HSCT) are related to
he donor, the graft, the patient, the transplant con-
itioning regimen, and prophylactic graft-versus-host
isease (GVHD) therapy. All of these factors affect
ematopoietic and immune recovery, GVHD and
raft-versus-leukemia (GVL), treatment related mor-
ality (TRM), relapse, and disease-free survival (DFS).
avorable risk factors identiﬁed by the authors of a
umber of signiﬁcant publications include the diagno-
is, cell dose, cytomegalovirus (CMV) negative serol-
gy, age, the HLA disparity, favorable remission sta-
us, CD34 cell dose, and absence of acute GVHD
aGVHD). For example, in a study of 191 children
ith acute myelogenous leukemia (AML) who re-
eived unrelated cord blood transplants, DFS at 42
onths when transplanted in complete remission
CR) 1 was 67%, in CR2 it was 49% and for later
tages of the disease was 24%. A study of 171 adults
ho received an unrelated cord blood transplant iden-
iﬁed favorable risk factors for survival and DFS as
emission status, ABO, and sex of patient (female
ecipients having more favorable outcomes). In an-
ther study of 262 adults with hematologic malignan-
ies who received a UCBT using a myeloablative
onditioning regimen, favorable factors as determined
n a multivariate analysis for DFS were CMV nega-
ivity, ABO compatibility, status of the disease at
ransplant, and the use of total body irradiation (TBI);
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Summary of IUCBT Symposium 1381lso, there was a trend for favorable outcome for
atients receiving 2  107 nucleated cells/kg body
eight. In a study of children with acute lymphoblas-
ic leukemia (ALL) in CR2 who received a UCBT, an
mportant factor was whether the ﬁrst relapse was on
r off chemotherapy. The DFS for those whose re-
apse occurred off therapy (n  65) was 45% and for
hose whose relapse was while on therapy (n 73) the
FS was 26%. In a recent analysis of 925 patients with
alignant disorders who received a UCBT, multivar-
ate analysis for TRM identiﬁed three favorable prog-
ostic factors: HLA 6 of 6 or 5 of 6, early and inter-
ediate phase of the disease, and the number of cells
nfused being 2  107/kg. Multivariate analysis for
verall survival (OS) also identiﬁed three favorable
rognostic factors: early and intermediate phase of the
isease, the number of cells infused as 2  107/kg,
nd negative CMV serology.
Dr. Guillermo Sanz reviewed the outcomes in 92
dults with hematologic malignancies who underwent
single unit UCBT at a single institution after my-
loablative conditioning using thiotepa, busulfan, cy-
lophosphamide or ﬂudarabine (Flu), and anti-thymo-
yte globulin (ATG). The cumulative incidence of
yeloid engraftment, grade III-IV aGVHD, and non-
elapse mortality (NRM) at 100 days was 90%, 18%,
nd 25% respectively. The cumulative incidence of
elapse and the probability of DFS at 3 years were
1% and 39% (median follow-up, 26 months). A mul-
ivariate analysis of prognostic factors of short term
utcome endpoints indicated that the absolute num-
er of CD34 cells infused had a marked effect on
eutrophil and platelet engraftment; the type of ATG
lympho vs. thymoglobulin) had a signiﬁcant effect on
latelet engraftment and aGVHD; and the develop-
ent of aGVHD had a signiﬁcant effect on platelet
ngraftment. A multivariate analysis of prognostic fac-
ors of long term outcome endpoints indicated that
ge, stage of disease, CD3 cells infused, condition-
ng regimen (Flu vs. no Flu), and development of
rade II-IV aGVHD all had a signiﬁcant effect on
RM. Patients with advanced disease or who had a
iagnosis other than CML had a higher relapse rate
nd the only variable that affected DFS was the stage
f disease at transplant. The authors concluded that
CBT of adults with a single and adequate unit and
sing highly immunosuppressive conditioning can
rovide the same engraftment rate and similar speed
f engraftment to that obtained in children. Also, the
umber of CD34 cells in the UCB unit is the most
elevant factor for engraftment. This factor must be
sed for the UCB unit of choice. The degree of HLA
ismatching does not seem as important in adults as
n children. Several outcomes after UCBT (speed of
ngraftment and risk of aGVHD, TRM, and relapse)
ere modulated by the conditioning regimen. Age had
major inﬂuence on NRM. The stage of the disease at aransplant was the major determinant of DFS. Finally,
he criteria for selecting the best CB unit for adults
eed urgent modiﬁcation.
Dr. Marcos de Lima reviewed the impact of host-
ersus-graft (HVG) HLA mismatch on outcomes of
BT. The authors of this presentation developed the
ypothesis that HLA mismatches in the HVG direc-
ion are likely to inﬂuence outcomes of unrelated
BT, in particular engraftment. They performed a
etrospective study of 91 patients with malignant or
on-malignant disorders who received CBT. The
onditioning regimen was myeloablative in 86 patients
95%). In pediatric patients the 1 year survival was
0% versus 70% (zero versus 1 mismatches, respec-
ively), P  0.3. In adult patients the corresponding
alues were 45% vs. 39%, respectively. Thus, in this
mall sample set, there was no statistically signiﬁcant
ssociation between number of graft-versus-host
GVH) mismatches and survival. There was, however,
higher cumulative incidence of grade II-IV aGVHD
mong adult recipients of larger grafts, with a similar
rend apparent in children. The authors concluded
hat evaluation of mismatches at a higher level of
esolution and in other HLA loci (HLA-C, -DQ,
DP) is warranted to better evaluate these histocom-
atibility effects on engraftment, incidence of GVHD,
nd immune reconstitution. A larger patient popula-
ion should be tested.
Dr. Mary Eapen discussed the risks and beneﬁts of
CB vs. bone marrow (BM) unrelated donor HSCT
n children with acute leukemia. She pointed out that
election of CB over BM remains controversial. For
one marrow transplants (BMT), studies have shown
hat there is signiﬁcantly higher mortality when there
s a mismatch at -A, -C or -DR loci. More speciﬁcally,
he data indicate that there is a 9-10% lower OS with
ach additional mismatch. That is, with 8 of 8 HLA
atched transplants, OS was 52%; with 7 of 8 HLA
atched transplants OS was 43% and for 6 of 8 HLA
atched transplants the OS was 33%. She reviewed a
tudy of 116 BMT patients who were compared with
03 CBT. All BM patients had an 8 of 8 allele matched
onor whereas only 7% of donor-recipient CB pairs
ere matched (low resolution at -A and -B loci and
igh resolution at -DR), 40% had a one antigen mis-
atch and 53% had a 2 antigen mismatch. The results
f the study indicated that, relative to matched BM, 1
ntigen mismatched CBTs had lower GVHD and
imilar rates of TRM, relapse, and LFS. Matched
BTs had less GVHD and TRM and higher survival
ates. However, small patient numbers prevent deﬁ-
ite conclusions. Two antigen mismatched CBTs had
ower GVHD, higher rates of early TRM, lower rates
f relapse and similar rates of LFS. The authors of the
tudy concluded that the data support use of 0-2 an-
igen mismatched CB grafts regardless of the avail-
bility of a matched BM donor in pediatric patients
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Summary of IUCBT Symposium1382ith acute leukemia. Also, that larger repositories of
B are needed to meet the increasing demand for
arger, partially HLA matched units.
Dr. Eliane Gluckman presented the results of a
tudy of unrelated CBTs in non-malignant diseases (n
268). The diagnosis in 48% of patients was a BM
ailure syndrome, 30% with severe combined immu-
odeﬁciency disease (SCID), and 22% had a meta-
olic disorder. HLA matching was done with low
esolution for -A and -B and high resolution for
DRB1: 17% of patients were matched, 43% had a
ne antigen mismatch, 36% had 2 antigen mismatches
nd 4% had greater than 2 antigen mismatches. For
eutrophil recovery, favorable prognostic factors were
1) 1 HLA disparity, (2) cell dose infused 3 
07/kg, and (3) diagnosis of SCID. For platelet recov-
ry, favorable prognostic factors were (1) 1 HLA
isparity, (2) diagnosis other than BM failure syn-
rome, and (3) cell dose infused 3  107/kg. For
rade II-IV aGVHD, only one favorable prognostic
actor was identiﬁed, HLA disparities 3. For sur-
ival, favorable factors were (1) negative CMV serol-
gy, (2) diagnosis other than BM failure syndrome, (3)
ells dose infused 2  107/kg, and (4) no more than
HLA disparity. Further data indicated that the re-
uirements for cell dose and HLA matching are dif-
erent in malignant and non-malignant diseases. In
on-malignant disease the optimal cell dose is 5 
07 at collection and 4  107 at infusion. Also, HLA
ismatches play a major role for engraftment,
VHD, and survival, and the effect of HLA mis-
atches is partially abrogated by increasing cell dose.
ESSION II. STRATEGIES TO IMPROVE
NGRAFTMENT AFTER UCBT
Dr. John Wagner reviewed factors having an im-
act on engraftment after UCBT. These include nu-
leated cell dose, CD34 dose, HLA match, GVHD,
istory of prior chemotherapy, graft T cell dose, use
f growth factors, host microenvironment, use of
ost-transplant cytotoxic agents, and development of
ost-transplant infection. He reviewed transplant data
rom 1994-2000 at the University of Minnesota (n 
02), which indicated a superiority of CD34 and
FU-GM dose over nucleated cell dose in predicting
ngraftment. There was a linear relationship between
D34 cell dose and the days to neutrophil recovery.
lso, patients with the lowest cell doses (speciﬁcally
1.7  105 CD34/kg) had the highest risk of graft
ailure. For platelet recovery, CD34 again had a
igniﬁcant effect as did CMV serostatus. Lessons
earned from this early study were that CD34 cell
ose is a major factor. These data led to a change in
inimum cryopreserved cell dose from 1 to 2.5  107ucleated cells/kg. HLA match was not a clear factor un this analysis (although too few patients were in the
/6 and 3/6 categories) and G-CSF may be important.
more recent and larger multi-center study
COBLT) included 316 patients between ages of 0.1
nd 17.9 years (median age  4.6 years) who were
ransplanted between 1999 and 2004. The results in-
icated that cell dose, HLA match (5-6/6 versus 4/6)
nd donor age are signiﬁcant factors. Eurocord regis-
ry data indicate that engraftment is affected by CMV
erostatus, stage of the disease, and cell dose infused
2  107/kg). There is an interaction between cell
ose and HLA match, i.e., one needs more cells to
chieve engraftment with increased HLA mismatches.
hen donor and recipient are matched (6 of 6) there
s no clear impact of cell dose, but when there are
ismatches, the affect of cell dose becomes apparent.
arly results from the NY Blood Center suggest that
lu may have a favorable affect on engraftment. A
ultivariate analysis in adults indicated that nucleated
ell dose 2.5  107/kg, HLA mismatch, absence of
lu, and use of methotrexate (MTX) adversely af-
ected neutrophil recovery. Different strategies are
eing developed to enhance engraftment including
ptimization of the peri-transplant therapy, improv-
ng HSC homing (e.g., CD26 inhibition, PTH, intra-
one marrow injection), co-infusion of haplo TCD
eripheral blood stem cells (PBSC) with UCB, use
educed intensity conditioning (RIC), and increased
ell dose through improved collection volumes, ex-
ivo expansion, or infusion of two partially HLA
atched units.
Dr. Mary Laughlin discussed the inﬂuence of HLA
isparity and graft lymphocytes on allogeneic engraft-
ent and survival after UCB transplants in adults. She
eported the results of a single institution prospective
hase II study in adults receiving unrelated UCB fol-
owing a myeloablative conditioning regimen. The
tudy was designed to test the hypothesis that UCB
raft lymphocytes may have an impact on rates and
inetics of donor engraftment. A secondary objective
as to prospectively determine the relationship be-
ween degree and nature of HLA mismatch in UCB
rafts and GVHD/patient survival. Results of this
arly phase II study indicated that graft nucleated cell
nd CD34 hematopoietic progenitor cell dose are
redictors of allogeneic engraftment and survival in
CB adult recipients. Univariate analyses demon-
trated that UCB graft infused cell doses of
D34, CD3 and CD34HLADRCD38
rogenitors correlated with donor neutrophil en-
raftment. Also, allele matching for HLA class II
esulted in improved event free survival (EFS) and
ecreased risk for aGVHD.
Dr. John Wagner reviewed results at the University
f Minnesota using double UCBT. As cell dose is a
imiting factor in the successful use of UCBT, two CB
nits were used to increase cell dose. The units must
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Summary of IUCBT Symposium 1383e partially HLA matched with each other and with
he patient. No more than 2 antigen mismatches are
llowed with the patient and between the two grafts.
he combined cell dose of the two units must be at
east 2.5  107 cells/kg. The preparative therapy in-
ludes TBI, Flu and Cy, and the post-transplant im-
une suppression is cyclosporine A (CSA) and myco-
henolate mofetil (MMF); all patients received growth
actor. In the initial phase I study, 23 of 23 patients
eceiving two units had neutrophil engraftment at a
edian of 23 days. Transient “double” chimerism
ccurs and in most, the unit that predominates early
n “wins.” Predicting which unit will win is not yet
ossible as there is no association with infusion order,
ononuclear cell dose, CD34 dose, CD3 dose, gran-
locyte-macrophage colony forming units (GM-
FU) dose, HLA, or ABO match. In a multivariate
nalysis, the only factor predictive of neutrophil en-
raftment was the combined CD34 cell dose. Using
ouble UCBT, engraftment is comparable to that in
hildren, 93% of adults are now eligible for UCBT as
ompared to 30% with a single UCB unit, if the
hreshold is 2.5  107/kg).
A retrospective analysis was done to determine
hat factor – use of Flu or coinfusion of UCB most
igniﬁcantly affected engraftment. The analysis in-
luded 147 patients with hematologic malignancy un-
ergoing ﬁrst transplants between 1994-2005. Results
f this study suggested that the combined cell dose is
he principal factor responsible for both engraftment
nd speed of neutrophil recovery. Although Flu is
ssociated with increased incidence of engraftment, it
s not statistically signiﬁcant. In the subgroup of pa-
ients receiving Flu/Cy/TBI, HLA-matching as well
s cell dose is responsible for the speed of neutrophil
ecovery.
Dr. Hal Broxmeyer reported on the effect of CD26
nhibition on CB engraftment. Inhibition of CD26/
ipeptidylpeptidase IV (DPPIV) with small peptides,
uch as Diprotin A or Val-Pyr enhance the capacity of
uman CB CD34 cells and mouse Sca1c-kitlin
M cells to respond to the chemotactic activity of
tromal cell derived factor in vitro, and they enhance
onor mouse BM HSC homing and engraftment of
ethally irradiated recipient mice in both a competitive
nd a non-competitive assay. Recent studies indicate
hat inhibition of CD26/DPPIV in human CB
D34 cells enhances their engraftment of nonobese
iabetic (NOD)/SCID mice. Also, Diprotin A pro-
uces enhancement of CD34 cord blood and G-CSF
obilized adult peripheral blood CD34 cells, respec-
ively, by pretreating donor CD34 cells, or treating
he recipient mice themselves. Pretreatment of le-
hally irradiated mice with Diprotin A enhances en-
raftment of untreated donor mouse cells. Future
tudies to enhance HSC engraftment will encompass
tudies in higher animals and human clinical trials. oDr. Ronald Hoffman discussed the expansion of
uman UCB SCID-repopulating cells using chroma-
in-modifying agents. The lack of net stem cell expan-
ion following in vitro exposure to cytokines could
esult from inability of cytokines to promote HSC
ivisions. The remaining bone marrow repopulating
otential of such expanded cell populations might be
rom cytokine unresponsive HSC. Previous ex-vivo
ttempts to alter HSC fate divisions in the presence of
variety of cytokine combinations or feeder layers
ave resulted over time in a loss of cells expressing the
tem cell phenotype and progressive loss of the num-
er of primitive progenitors cells quantiﬁed using a
ariety of surrogate stem cell assays. Further, silencing
f genes has been shown to be accompanied by DNA
ethylation of a gene’s promoter and by histone
eacetylation in regions controlling the genes of in-
erest. Studies were carried out to investigate whether
he addition of two chromatin-modifying agents,
-aza-2=-deoxycytidine (5azaD) and trichostatin A
TSA), to CB CD34() cells in culture results in
xpansion of the numbers of SCID repopulating cells
SRC). Results indicated that the program of HSC in
itro can be epigenetically modiﬁed to change their
ate by agents affecting DNA hypomethylation and
cetylation. Epigenetics appears to play a role in de-
ermining the transcriptional options of HSCs and
hanging the behavior of these cells in vitro. Finally,
he use of chromatin modifying agents favors symmet-
ic cell division of CB HSC. Thus, ex-vivo expansion
trategy using chromatin-modifying agents provides a
otential avenue by which to expand the number of
SC in single CB unit for use as an alternative source
f HSC grafts for adult recipients.
Dr. Tracey O’Brien presented data indicating that
SK-3 regulates ex-vivo expansion and engraftment
f UCB HSC through activation of Wnt signaling.
ast experience has indicated in animal models that
hort term reconstituting HPC are expanded at the
xpense of longer term repopulating cells required for
urable engraftment. In clinical trials engraftment has
een no faster despite infusion of expanded cell num-
ers suggesting loss of function and/or homing of
SC/HPC in the expansion process. There are data
ndicating that Wnt signaling positively regulates self-
enewal of murine HSC. An alternate approach to
chieve Wnt activation is by inhibition of glycogen
ynthase kinase-3  inhibition, which prevents degra-
ation of -catenin. GSK-3  inhibition suppresses
x-vivo proliferation of UCB cells induced by cyto-
ines but improves the repopulating capacity of UCB.
e have explored the role of GSK-3 inhibition and
nt activation as a means to expand ex-vivo human
CB cells. We have shown that GSK-3  inhibition
uppresses ex-vivo proliferation of UCB cells induced
y cytokines but improves the repopulating capacity
f UCB. Using a synthetic GSK-3 inhibitor (6-bro-
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Summary of IUCBT Symposium1384oindirubin 3’-oxime; BIO) co-cultured with UCB
D34 cells, we demonstrate that GSK-3  inhibi-
ion suppresses ex-vivo expansion of committed
PCs, whereas increasing the pool of the most prim-
tive progenitor/stem cells. UCB C34 cells cultured
n BIO results in the accumulation of -catenin and its
elocation from the cytoplasm to the cell nucleus. In
ddition up-regulation of c-myc and HoxB4 genes both
nown -catenin targets involved in the regulation of
tem cell renewal, was observed. Using the ‘human-
zed’ NOD/SCID mouse model we have demon-
trated both expansion and preservation of function
ith increased numbers of engrafting BIO treated
uman CD34 UCB (120-fold expansion) compared
o control cells (45-fold expansion). In addition, in-
reased output of myeloid, lymphoid and megakaryo-
ytic progenitor cells was observed in NOD/SCID
ice that received BIO-treated UCB cells. Thus, us-
ng a humanized NOD/SCID mouse model we have
hown that activation of the Wnt pathway through
SK-3 inhibition improves the repopulating ability
f human UCB hematopoietic progenitor/stem cells.
Dr. Colleen Delaney discussed Delta1: A notch up
n CBT? Notch signaling is generally capable of in-
uencing the ability of a cell to progress from a less to
more differentiated state in response to speciﬁc sig-
als, e.g. growth factors. A role for Notch in hemato-
oiesis was initially suggested by detection of the hu-
an Notch1 gene in CD34 or CD34lin- human
ematopoietic precursors. Retrovirus-mediated ex-
ression of a constitutively active form of Notch 1
esulted in enhanced self-renewal of hematopoietic
rogenitors, and activation of endogenous Notch re-
eptors in primary murine hematopoietic progenitors
LSK cells) by culture in the presence of immobilized
otch ligand (Delta1) resulted in a multi-log increase
n short-term lymphoid and myeloid repopulating
ells. Similarly, culture of CB progenitors in the pres-
nce of Notch ligand results in 100 fold increase in
D34 cells with short-term and possibly long term
OD/SCID repopulating ability. Optimization of the
otch-mediated expansion system was carried out with
he goal of providing cells that rapidly engraft and
vercome the delay in hematopoietic recovery after
SCT. A clinical trial is underway using double CBT
ith a fully myeloablative Cy/Flu/TBI conditioning
egimen. An unmanipulated unit is infused ﬁrst fol-
owed by expanded cells given 4 hours later. Three
atients have been enrolled in the study and data are
vailable on the ﬁrst two. Both were adults with AML
n CR1. Cell expansion resulted in a 791 fold expan-
ion in patient #1 and a 743 fold expansion in patient
2; CD34 expansion was 210 fold for patient #1 and
74 fold for patient #2. Patient #1 engrafted on day
9 and patient #2 engrafted on day 16. Both pa-
ients had a consistent absolute neutrophil count
ANC) above 100 by day 7 post-transplant. Platelet sngraftment 20K occurred on days 53 and 32,
nd 50K on days 68 and 41 in the ﬁrst and
econd patient, respectively. In patient #1 weekly chi-
erism data indicated that all cells were from the
xpanded unit on day 7 and again on day 14; by
ay 21 there was no longer engraftment by the
xpanded cells. In patient #2 the non-manipulated
nit did not begin to contribute to the engraftment
ntil after day 14 and, until that time, 100% of the
ngrafted cells were from the expanded unit. Using
he same preparative regimen and post-transplant im-
unosuppression, the median time to engraftment
as 27 days for 9 patients receiving double CBTs but
ithout using expanded cells.
Dr. Elizabeth Shpall discussed CB expansion and
ndicated that to date no infusional toxicity has been
ssociated with transplantation of expanded CB; time
o platelet engraftment may be reduced but neutrophil
ngraftment is still three weeks; CD34 and total cell
osses with positive selection are substantial; and
herefore alternative cord expansion strategies are
eeded. Mesenchymal stem cells (MSC) can differen-
iate into bone, adipocytes, cartilage, functional mus-
le, and liver cells. MSC may provide cellular and
xtracellular components of the stem cell “niche” ab-
ent in current liquid expansion protocols, thereby
mproving CB expansion, engraftment, and poten-
ially reducing the rate or severity of GVHD. Studies
re underway in which CB MNC are co-cultured with
SC. The co-culture system, compared with the liq-
id culture system, has produced superior results in
xpansion of TNC, CFU, CD34, CD133, CAF-
wk2 and CAFCwk6. A clinical trial is soon to begin
o determine if cells expanded in the co-culture system
an improve time to neutrophil and platelet engraft-
ent and engraftment failure rate; secondary end-
oints are GVHD, infections, immune reconstitution,
ay 100, and OS.
Dr. David Scadden discussed methods of enhancing
he engraftment of stem cell grafts. The stem cell
iche hypothesis suggests that stem cell persistence
epends upon engagement of a specialized anatomi-
ally deﬁned microenvironment. A niche is an archi-
ectural place where stem cell survival and replication
re fostered and where interaction between heterolo-
ous elements is dynamic and may be transient. Mod-
fying parathyroid hormone (PTH) receptor geneti-
ally can lead to an increase the number of stem cells
n a mouse by about 2 fold. PTH given as a once daily
ose immediately following transplantation in a mu-
ine model resulted in improved cellularity in the
arrow, an increase in the stem cell pool, and greater
bility to tolerate the transplant. Data indicate that
TH in an animal model improves production of stem
ells, improves preservation of stem cells after chemo-
herapy, and improves efﬁciency of engraftment of
tem cells. Experiments in Cynomolgous monkeys (n

w
4
p
h
t
w
m
f
b
i
a
t
a
m
e
i
i
w
c
w
b
t
1
p
N
f
d
i
n
a
T
T
g
U
u
b
i
a
i
t
w
g
t
d
m
3
t
	
t
O
o
m
g
m
f
p
7
p
i
r
L
s
r
i
c
U
i
h
r
t
S
A
b
c
a
t
c
t
m
E
t
a
a
3
c
p
s
d
o
o
m
T
r
f
i
t
d
m
n
a
m
a
c
W
H
p
w
Summary of IUCBT Symposium 13856) in which conditioning plus allogeneic transplants
ere performed with and without daily PTH (d 7 to
9) indicated increased cellularity, and marked im-
rovement in immunologic recovery. Patients who
ad failed mobilization protocols for autologous
ransplant were treated with PTH; 7 of 15 patients
ho had failed one prior mobilization had an adequate
obilization after PTH, and 2 of 5 patients who had
ailed 2 mobilizations had a successful subsequent mo-
ilization procedure. The study of the effects of PTH
s being extended to patients who are to receive a dual
llogeneic CB transplant to see if PTH can improve
he outcome.
Dr. Ka Wah Chan discussed primary graft failure
fter unrelated donor CB transplants: risk factors and
anagement. The deﬁnition of engraftment is recov-
ry of ANC500/l with documented donor chimer-
sm. Primary engraftment failure is deﬁned as no ev-
dence of recovery of ANC 500/l, (except those
ith autologous recovery), or 5% donor cells on 2
himerism studies (PCR/STR method), performed
eekly, beginning 3rd - 4th week. Patients who die
efore day 28 are not evaluable. Among 100 UCBT
ransplants 6 died early, 83 engrafted and there were
1 primary graft failures. An analysis was performed of
ossible risk factors leading to primary graft failure.
one of the following features were statistically dif-
erent among patients who engrafted, and those who
id not: patient age or weight; TNC, CD34, or CFU
n the graft; a diagnosis of a malignant or non-malig-
ant disorder; inclusion or not of TBI in the prepar-
tive regimen; or HLA match of 5 of 6 or 4 of 6.
he approach to primary graft failure at the Texas
ransplant Institute is as follows: A backup autolo-
ous marrow is not collected. Instead, a second
CBT is used as rescue (sooner rather than later)
sing the most readily available unit with ﬁrst priority
eing cell dose but also important are HLA match and
mmediate shipment. The patient’s marrow is usually
plastic, so emphasis of the preparative regimen is on
mmunosuppression. The clinical outcomes of 11 pa-
ients with primary graft failure were as follows: two
ere not transplant candidates because of active fun-
al pneumonia, or recurrent leukemia and these pa-
ients died 35 and 62 days post transplant. Nine chil-
ren went on to second unrelated donor CBT. The
edian time to the second UCBT was 55 days, range
3-95 days. Six patients were treated with a prepara-
ive regime that included CY/Flu/TBI (2Gy),
ATG. Two patients with aplastic anemia were
reated with TBI (6Gy), CY and ECP or Campath.
ne patient received Campath and Flu. There was
ne early death (day12) and the other 8 patients had
yeloid engraftment (median day 15), platelet en-
raftment (median day 92), and complete donor chi-
erism. However, late infectious complications af-ected 7 of the 8 survivors. The current status is that 5 tatients are alive at a median of 1,095 days (range
58-1,328 days). Chronic GVHD was diagnosed in 6
atients and was extensive in 5; the performance status
s 30-90% (median 70% - Lansky scale). Two deaths
esulted from respiratory failure, one was from EBV-
PD, and one was due to Pseudomonas sepsis. Conclu-
ions reached are that primary graft failure is a serious
isk of UCBT. A back-up donor source should be
dentiﬁed before start of procedure; the lack of donor
himerism early on is predictive of GF, an early 2nd
CBT was a feasible therapeutic option, and using an
mmunosuppressive preparative regimen resulted in
igh engraftment rate. Survivors experienced a greater
isk of extensive chronic GVHD (cGVHD) and mul-
iple infections and viral reactivation post-transplant.
ESSION III. CORD BLOOD BANKING, MANIPULATION
ND UNIT SELECTION
Dr. Eliane Gluckman discussed how to choose the
est CB unit for unrelated CBT. It is important to
onsider whether the transplant is for an adult or child
nd one must also consider the diagnosis and stage of
he patient’s disease. It is critical to be objective when
omparing with other sources of stem cells. The cri-
eria of choice are nucleated cells, CD34 cells, HLA
atching at high or low resolution, and other factors.
urocord recommendations (2007) are to ﬁrst look at
he number of cells that should be 3  107 NC/kg
nd/or2 105 CD34/kg. Second, one should look
t HLA matches: 0-1 mismatch is better than 2 (avoid
-4 mismatches). Class I mismatches are preferable to
lass II mismatches. Increase the number of cells to
artially overcome HLA mismatches. Then one
hould adopt to the graft indication: For malignant
iseases the cell dose is the most important factor for
utcome. A minimum of 3  107 NC/kg at collection
r 2  107/kg at infusion must be obtained. HLA
ismatches increase the risk of engraftment delays,
RM and cGVHD and decrease the risk of relapse
esulting of an absence of the role of HLA mismatches
or survival. The type of HLA mismatches did not
nﬂuence outcomes and increasing cell dose abrogates
he effect of HLA mismatches. For non-malignant
iseases the requirements for cell dose and HLA
atching are different than in malignant disorders. In
on-malignant disease cell dose is higher at 4.9  107
t collection and 3.5  107at infusion; HLA mis-
atches play a major role for engraftment, GVHD,
nd survival, and are partially abrogated by increasing
ell dose. The CB selection procedures from Dr. J.E.
agner are quite similar and are as follows: Sort by
LA match showing only those CB units that are
otentially 4 of 6 matches, then sort by cell dose
ithin each HLA matched category, and then list only
hose units that have a cell dose 1.5  107/kg. Use a
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Summary of IUCBT Symposium1386ingle if 6 of 6 unit is identiﬁed with a cell dose 3.0
107/kg, use a single if 5 of 6 unit is identiﬁed with
cell dose4.0 107/kg, and use a double cord if not
nough cells in a single cord, using units as closely
atched as possible with a total cell dose 3.0 
07/kg.
Dr. Juliet Barker’s presentation was entitled: A “no
ash” albumin-dextran dilution strategy for UCB
haw for adolescent and adult UCB transplant recip-
ents: Superior to wash? Some studies suggest that
ashing the CB unit is not necessary in adults and that
lbumin dilution is a good alternative. However, some
CBT centers are resistant to change. The potential
dvantages of an albumin-dilution thaw strategy over
ashing are reduced UCB manipulation; it is faster; it
s simpler; there is reduced cell loss (washing is re-
ponsible for half of post-thaw cell loss); and there is
o risk of bag break in centrifuge. Advantages over
edside thaw are that it is performed in the controlled
nvironment of a cytotherapy lab, it avoids prolonged
xposure to high concentrations of DMSO at room
emperature, it allows for immediately taking and dis-
ributing samples for CD34 analysis and research,
nd it results in the ability to obtain cell count and
erform trypan blue testing prior to infusion. A pro-
pective study was performed with the hypothesis that
lbumin dilution was comparable to washing in terms
f post-thaw TNC/CD34 cell dose and engraftment.
he study was initially restricted to RBC depleted
nits but was subsequently modiﬁed to include RBC
ontaining units. Nineteen patients were studied, each
f whom received a double CBT. Results indicated
hat the albumin-dilution thaw of UCB was compara-
le to wash with centrifugation for TNC yield, infu-
ion reaction proﬁle, and engraftment. It was faster,
ore efﬁcient, reduces technologist time, speeds time
o patient infusion, and reduces potential for cell loss.
herefore, is it superior to wash for adult UCBT? It
hould facilitate center-center standardization and is
o be investigated in CIBMTR sponsored multi-cen-
er prospective study of adult double unit UCBT.
inally, reduced cell loss from albumin-dilution strat-
gy makes taking of a small sample for research ethi-
ally acceptable. Unanswered questions are whether it
hould be utilized in smaller children (patients40 kg
ere not tested). Also, the incidence of aGVHD
eems to be a bit lower so that there is a possibility of
ualitative effects on GVHD.
ESSION IV. CONDITIONING REGIMENS
Dr. Richard Champlin reviewed nonmyeloablative
CT for hematologic malignancies – considerations
or CBTs. The fundamental hypothesis for nonmy-
loablative SCT is to intentionally decrease the inten-
ity of the preparative regimen to reduce toxicity, and pllow GVL to eradicate the malignancy. Some regi-
ens are truly nonmyeloablative and the patients are
apable of repopulating their marrows without a
ransplant. Other regimens are RIC but are myeloa-
lative and the patient requires a transplant. Patients
eceiving truly nonmyeloablative regimens have a
ower rate of aGVHD and there is a trend toward a
ower rate of cGVHD. The results of nonmyeloabla-
ive BMTs have indicated reduced toxicity and re-
uced GVHD; similar infections occur, but these are
enerally responsive to therapy. There is a lower rate
f TRM and the use of such transplants can extend the
se of HSCT to patients up to 75 years of age. Greater
mmune suppression is needed to reliably achieve en-
raftment in CBT. Regimens effective for matched
ibling and matched unrelated transplants may not be
ufﬁciently immunosuppressive for UCBT. In a Bu/Flu
egimen, there was a 3% rejection rate for sibs/
atched unrelated donor (MUD), but 
40% with
CBT. RIC effective in UCBT include Cy/Flu/TBI
nd Melphalan-thiotepa-Flu. There is a potential ben-
ﬁt of HLA mismatches in UCBT in that the frequent
se of mismatched units provides a target for GVL
nd results in a lower relapse rate. Elderly patients
ith AML have a dismal prognosis, but a trial of
educed intensity BMT indicated no early TRM and a
0% survival at 60 months (patients must be in remis-
ion prior to transplant). This is in contrast to 
5%
urvival at two years for standard chemotherapy. Fur-
her studies of reduced intensity transplants in this
roup of patients are in progress. Another category of
atients who have been helped by non-myeloablative
onditioning regimes is indolent lymphoma. Using a
onditioning regimen of Flu, CSa and rituximab for
atients with follicular lymphoma (FL), 90% are alive
t 90 days, which is much improved over the results
sing a myelablative regimen. Studies are also in
rogress for MCL and chronic lymphocytic leukemia
CLL). Certain diseases, such as chronic myelogenous
eukemia (CML), (CLL) and LGL, are more sensitive
o graft-versus-malignancy than others and these dis-
rders are the prime candidates for reduced intensity
ransplants.
Dr. Claudio Brunstein discussed nonmyeloablative
CBT. The hypothesis underlying nonmyeloablative
CB transplantation is that despite the differences
n UCB alloreactivity, UCB has enough immune cells
o mediate engraftment after nonmyeloablative con-
itioning. There is a growing number of reports of
onmyeloablative UCB transplants, especially for
dult patients. At the University of Minnesota, a study
as performed using Cy/Flu/TBI for the conditioning
egimen and CSa and MMF for post-transplant im-
unosuppression. ATG was added for patients who
ad not received chemotherapy within 3 months of
ransplantation. Patients receive a double UCB trans-
lant if no single graft is big enough. HLA matching
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Summary of IUCBT Symposium 1387s done at the antigen level for -A and -B loci and at
he allele level for -DRB1. Using this study design
bout 80-85% of patients received two UCB units.
he sustained donor engraftment rate for 161 patients
as 87%. The incidence of grade II-IV aGVHD was
4% and Grade III-IV was 18%. The 6 month TRM
as 18% and at 3 years it was 25%. The progression-
ree survival (PFS) for patients who received two units
as 39% and for those receiving one unit was 24% (n
110, P  .05). OS was 45% for those receiving
ither 1 or two units (n  161). A further study was
erformed comparing the outcomes after reduced in-
ensity transplantation using UCB versus sibling
BSC for de novo and secondary AML. Results indi-
ated that the OS was not signiﬁcantly different when
omparing the two HSC sources. In summary, UCB is
n effective alternative source of HSC for NMA trans-
lantation. Patients who need nonmyeloablative
ransplant and who do not have a suitable sibling or
nrelated donor should be considered for UCB trans-
lantation. Larger numbers of patients will help fur-
her determine the role of UCB transplantation in
lder patients and those with pre-existing high risk
linical features.
Dr. Vanderson Rocha discussed a RIC regimen after
ingle unrelated CBT for adults with hematological
alignancies. Unrelated CBT using RIC regimen has
een proposed in order to shorten the aplasia period
nd decrease TRM in adult patients with high risk of
ying of toxicity. Since cell dose is a major limiting
actor in UCBT, concerns have been raised in the use
f CB cells in RIC. Also, another concern is the GVL
ffect from lower incidence of GVHD after UCBT.
here are no data available in single RIC UCBT
nalyzing risk factors of outcomes. A retrospective
tudy of 142 patients with hematologic malignancies
as performed. The median age of patients was 44
ears (range, 16-76). Twenty-three conditioning reg-
mens and a number of regimens for GVHD prophy-
axis were used in this registry based study. The me-
ian days to neutrophil recovery was 20 days (5-56)
nd for platelet recovery was 38 days (15-171). A
ultivariate analysis for neutrophil recovery indicated
hat conditioning with FluENDXTBI was a sig-
iﬁcant factor as was HLA 0-1 vs. 2-3-4. Other factors
ncluded in the model that were not signiﬁcant were
ell dose, status of the disease and female sex. aGVHD
ccurred in 29% and cGVHD in 40%. TRM at day
00 was 28% overall and was 14% with a cell dose of
2.8  107/kg and 39% with a cell dose of 2.8 
07/kg. Multivariate analysis indicated that the condi-
ioning regimen and cell dose were signiﬁcant factors.
elapse at one year was 53% for patients with ad-
anced disease and 36% for those with early or inter-
ediate disease. OS was 43% and DFS was 32%. The
FS varied depending on the HLA match: 67% when
atient and donor were HLA matched, 46% with 1 1LA disparity, 21% with 2 HLA disparities, and 12%
ith 3 HLA disparities. DFS was 42% when trans-
lanted in remission and 23% if not in remission.
ith TBIFluENDX the DFS was 44% and with
ther conditioning regimens it was 23%. Conclusions
eached in this retrospective based registry study and
igh risk group of patients were that the results of
ingle RIC-UCBT are encouraging. Cell dose and
LA remain important factors in this setting. For this
eason probably results can be improved with double
ords and better HLA matching. Importantly, the
ype of conditioning (FluENDXTBI) is associated
ith decreased TRM and better DFS. Use of busulfan
as associated with increased TRM. Immunosuppres-
ion after RIC-UCBT should be carefully evaluated in
igh risk patients of relapsing without GVHD.
Dr. Karen Ballen presented the results of a study of
utcomes of adult patients after double CBT using an
IC regimen which consisted of Flu, melphalan and
abbit ATG. The minimum combined cell dose was
.7  107NC/kg pre-freeze. GVHD prophylaxis in
rotocol #1 consisted of CSa and MMF (21 patients),
nd in protocol #2 it consisted of sirolimus and ta-
rolimus (22 patients with 100 days follow up). The
edian age for protocol #1 was 49 years (range 24-63)
nd, for protocol #2 was 53 years (19-64). All patients
ad hematologic malignancies. For the two protocols
he median days to engraftment for ANC 500 were
0 or 21, respectively. Days to platelets20K were 41
nd 47 days; to platelets 100K were 65 and 125,
espectively. There were two graft failures in protocol
1 in patients who had aplastic anemia (AA) and MDS
nd who had not received prior cytotoxic therapy. The
GVHD rate for grades II-IV were 40% and 14%,
espectively for the two protocols and, for grades
II-IV, the rate was identical at 5%. The cGVHD rate
as 34% and 20%, respectively and the extensive
GVHD rate was 20% and 6%, respectively. For
rotocols #1 and #2, the one year OS was 67% and
3%, one year DFS was 67% and 51%, and relapse
ate was 19% and 34%, respectively. The TRM was
4% for both protocols. Chimerism analysis indicated
hat a single CB donor predominated in 76% of pa-
ients by day30. By day90 one unit was detectable
n 72%, both CB units in 18% and a single CB unit
nd host cells in 10%. Predictors of the predominant
nit were (1) ﬁrst unit infused, (2) higher CD34
ount and (3) higher NC/kg. A number of factors led
o some patients who had an indication for a trans-
lant but who did not receive a transplant: Six patients
ad no allele level match, two patients had no antigen
evel match, grafts for 3 patients had an inadequate
ell dose, there were insurance issues for 2 patients,
rogressive disease in 4 patients, and another donor
ource in 9 patients. In conclusion, double CBT with
his RIC regimen are well tolerated with TRM of
4%. Low relapse rate with low risk of GVHD sug-
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Summary of IUCBT Symposium1388ests preservation of GVL effect, and the risk of
VHD may be lower with the use of sirolimus/ta-
rolimus.
ESSION V. IMMUNE RECONSTITUTION
ND INFECTIONS
Dr. Bruce Blazar reviewed the topic of infection
nd immune reconstitution after HSCT: Challenges
nd opportunities. Despite hematopoietic engraft-
ent and recovery of marrow function, recipients of
ematopoietic cell transplants have prolonged defects
n generation of functional T and B lymphocytes.
hemoradiotherapy- and GVHD- induced epithelial
ell injury introduces a portal for bacterial, fungal, and
iral infections. Bacterial products result in macro-
hage activation and the release of pro-inﬂammatory
ytokines which may contribute to or resemble
VHD. An innate and adaptive immune system re-
ponse is needed to eliminate infectious pathogens. A
ajor cause of post-BMT immune deﬁciency is the
oss of thymopoietic capacity, and impaired T cell
ecovery as a result of factors such as age, radiation, or
VHD. Damage to thymic epithelial cells by pre-
MT conditioning impairs the ability of the thymus
o generate mature T lymphocytes after BMT. Ap-
roaches to lessen the injury or hasten the repair of or
eplace thymic epithelial cell or stromal elements or
heir products represent a promising strategy to speed
eripheral T cell reconstitution and function.
Dr. Paul Szabolcs presented data regarding a mul-
ivariate analysis of patient and graft speciﬁc factors
mong 330 recipients of unrelated cord blood trans-
lant (CBT) to predict risk of death from opportunis-
ic infections in the ﬁrst 6 months after CBT. Cord
lood is unique because of a high frequency of highly
roliferative primitive stem cells paired with “naïve”
ymphocytes. To determine the impact of patient and
raft-speciﬁc factors on 6-month post-unrelated CBT
I-related mortality we reviewed all consecutive pe-
iatric patients transplanted at Duke University Med-
cal Center between June 1999 and Oct. 2005. Three
undred thirty (330) consecutive pediatric recipients
f single unrelated CB grafts were identiﬁed. Those
eceiving a second transplant for primary graft failure
ere not analyzed. Two hundred twenty (220) of the
30 patients (67%) were alive at 6 months. Of the 110
hildren who died by 6 months, 64 patients (58%)
ere identiﬁed with OI (viral, fungal infections) im-
licated as a cause of death. The 46 patients who died
rior to 6 months and for whom OI was not impli-
ated as a cause of death were omitted from the study
ata set, resulting in 284 patients. Of these 284 pa-
ients, 200 patients (77%) were alive at 6 months and
4 (23%) died at or before 6 months with cause of
eath related to OI. Twenty two (22) patients died ielated to adenovirus infection and twelve (12) from
MV infection, rendering these two viruses the cause
n50% of all OI related deaths. A logistic regression
odel was used to investigate the impact of ten de-
ographic and clinical characteristics on the risk of
eath from OI by 6 months post unrelatd CBT. These
otential predictors were sex, race, age at unrelated
BT, CMV serology, HLA mismatches (2-3 vs  1),
alignancy, TBI, total graft cell dose/kg, CD34
raft cell dose/kg and CD3 graft cell dose/kg. In
nivariate analyses, sex, race and TBI did not predict
-month death from OI. Malignancy (P  .07) was
arginally associated with a greater probability of
-month death from OI. Malignancy without TBI was
lso associated with a marginally higher probability of
-month death due to OI (P  .04). A signiﬁcantly
reater probability of 6-month OI-related death was
ssociated with CMV positive serology (P  .0001),
reater HLA mismatch (P .006), and older age (P
0009). Higher total graft cell dose (P .001), CD34
ell dose (P  .014) and CD3 cell dose (.014) were
ssociated with lower probability of death from OI at
months. Multivariate analyses were performed:
odel 1 included; CMV (P  .0004), HLA mismatch
P .042) and age (P .03). Model 2 included; CMV
P  .0001), HLA mismatch (P  .005) and malig-
ancy without TBI (P  .04). Since total graft cell
ose, CD34 cell dose and CD3 cell dose were
ighly correlated, each of these variables was intro-
uced into models 1) and 2) separately. Total graft cell
ose was the strongest predictor when cell dose vari-
bles were added to Models 1 (P  .0097) and 2 (P 
004). CD34 cell dose contributed less signiﬁcantly
o both models (P  .02 both models). CD3 cell
ose did not signiﬁcantly contribute to Model 1 and
as marginally signiﬁcant in Model 2 (P  .05). The
ercent concordance among these models ranged
rom 71%-75%. Thus, 6-month death from OI after
ingle cord unrelated CBT in children can be pre-
icted by the following risk factors: older age, positive
MV serology,1 HLA mismatch, malignancy with-
ut TBI, lower graft cell dose (total, CD34 and
D3). Sex, race, and TBI alone do not predict
-month death from OI. In summary, opportunistic
nfections, (most being viral) are the most prevalent
ause of death in the ﬁrst 6 months after UCBT. This
nalysis of 330 consecutive patients demonstrates that
atient and graft-speciﬁc factors have a signiﬁcant
mpact on 6-month mortality from OI. Potential strat-
gies to reduce OI related mortality are to increase
ngraftment with improved homing, an increased cell
ose and/or ex-vivo expansion of stem/progenitor
ells; enhance immune recovery by improving surviv-
l/homeostatic expansion of infused lymphoid cells,
oosting thymic output, and reducing GVHD; and
ncrease T cell dose/adoptive therapy by ex-vivo ex-
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Summary of IUCBT Symposium 1389ansion of broad unprimed T cell repertoire and/or
ntiviral, antifungal CTL generation in vitro.
Dr. Krishna Komanduri presented data indicating
hat delayed immune recovery after UCBT is charac-
erized by thymic regeneration failure. A prospective
tudy of T cell immune reconstitution was performed.
amples were obtained from 32 patients (of 34 en-
olled), median age: 33.5 years (7-57); 28 patients
dults. The median follow-up was 221 days. Diag-
oses were AML/MDS (16), CLL (2), CML (2), HD
8), and non-hodgkin lymphoma (NHL) (4). Patients
ere heavily pretreated. All but one patient received a
yeloablative conditioning regimen. Primary im-
une recovery endpoints were immunophenotypic
nalysis of T cells, B cells, NK cells; assessment of
unctional T cell responses using cytokine ﬂow cytom-
try (stimulation with superantigen and CMV anti-
ens); assessment of thymic function (TREC as-
ay); and naïve and memory maturation phenotyping.
esults indicated decreased to absent thymic function
t baseline, no detectable thymic recovery in 24 of 26
ubjects, only one subject with signiﬁcant thymopoi-
tic recovery, thymopoiesis reduced relative to other
CT recipients (despite lower age of CBT recipients,
3 vs. 50). Thus, thymic regeneration failure charac-
erizes this group of cord blood SCT recipients. Im-
roved CBT immune recovery can result from pro-
pective studies characterizing the effects of age, stem
ell dose, and HLA matching on T cell recovery;
oving beyond “monofunctional” assays to examine
unctional T cell recovery; optimization of ex vivo
xpansion strategies to maximize the recovery of T
ell progenitors (e.g., using NotchL); use of thymo-
rotective (KGF) and thymopoietic (GH, leuprolide,
L-7) agents; and infusing antigen-speciﬁc T cells in
onor grafts.
Dr. Tomohiro Morio discussed a strategy to combat
pportunistic infections after UCBT. Current data
ndicate that the risk of serious infection after pediat-
ic UCBT is comparable to that with unmanipulated
M; there is a marked increased risk of EBV-related
omplications with the addition of ATG to a nonmy-
loablative conditioning prior to URCBT; 24 of 40
dult patients who underwent CBT developed VZV
eactivation at a median of 5 months after CBT; there
s a high incidence of HHV6 infection (7 of 10) with
high viral load in CBSCT recipients; and positive
MV antigenemia was seen in 19 of 24 sero-positive
dults patients at a median of 42 d after CBT. A
CR-based system for rapid and sensitive detection of
ultiple viruses detects more than 20 viruses in one
un; it is rapid with less than 2 hours from extraction
o data analysis, sensitive with a detection level of at
east 10 copies/sample; and costs less than $25. Expe-
ience with the use of this system indicates that it
rovides a economical, rapid, and sensitive method for
onitoring multiple pathogens; that scheduled mon- Gtoring would be beneﬁcial for detection of virus in-
ection at early stage; that infection with multiple
athogens was less in CBT-recipients than that in
MT/PBSCT recipients; and all the CBT-recipients
ith multiple virus infections showed profound im-
unodeﬁciency.
ESSION VI. NON-HEMATOPOETIC STEM CELLS
Dr. Mark Weiss presented a review lecture enti-
led, “Stem cells in the umbilical cord matrix: isolation
nd characterization.” Non-hematopoietic cells in the
mbilical cord or CB include mesenchymal stem cells
MSCs), USSCs, BioE’s cells, and VSLE. From the
mbilical vein one can obtain endothelial cells and
SCs. Wharton’s Jelly contains umbilical cord matrix
ells and perivascular cells. The amniotic ﬂuid and the
lacenta and decidua also contain stem cells. The ISCT
orking group deﬁnition of MSCs is that they are plas-
ic-adherent; their surface phenotype is CD34, CD45,
LA-DR negative, and CD29 (SH3) – CD105 (SH2),
D73 (SH4), HLA-class I positive; and they are mul-
ipotent, able to differentiate to bone, cartilage, adi-
ose, and muscle. MSCs play a role in immune mod-
lation, hematopoietic support (ex-vivo expansion of
SCs, enable engraftment of HSCs when co-grafted),
nd homing to pathology. Animal studies suggest
hat umbilical cord matrix cells may enable engraft-
ent of HSCs and may have therapeutic effects in
isorders including breast cancer, Parkinson’s dis-
ase, global ischemia brain damage (stroke), retinal
amage, and myocardial ischemia. The mechanism is
ot well-understood and may include immune modu-
ation and growth factor/cytokine effects.
Dr. Mariusz Z. Ratajczak discussed the morpho-
ogical and molecular characterization of a novel pop-
lation of CXCR4SSEA-4Oct-4 very small em-
ryonic-like (VSEL) cells puriﬁed from human CB.
ecently we identiﬁed in murine BM a homogenous
opulation of rare (
0.01% of BMMNC) Sca-1
XCR4 lin CD45 cells that express, by RQ-PCR
nd immuno-histochemistry, markers of pluripotent
tem cells. They display several features typical for
rimary embryonic stem cells such as i) a large nuclei
urrounded by a narrow rim of cytoplasm, and ii)
pen-type chromatin (euchromatin) that is typical for
mbryonic stem cells. These cells (
2-4 m in diam-
ter) were named very small embryonic-like (VSEL)
tem cells. A new two step isolation procedure is used
o purify a similar population of cells from human CB,
hich is based on isolation of CB mononuclear cells
CB MNC) by hypotonic lysis and multiparameter
ACS sorting. In vitro cultures of CB-VSEL are able
o grow neurospheres that gave rise to neuronal lin-
ages (beta-III tubulin, nestin, O4, MBP,
FAP) and cardiomyocytes (beta-myosin heavy
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Summary of IUCBT Symposium1390hain, alpha-sarcomeric actin). Based on this we con-
lude that CB contains VSEL and that the majority of
hese CB VSEL are lost during routine procedures
mployed currently for banking of CB MNC. We
onclude that CB tissue/organ regenerating potential
ay be much higher than initially postulated if the
roper fraction of CB MNC cells enriched in VSEL is
mployed.
Dr. Mervin C Yoder discussed high proliferative
otential endothelial progenitor cells found in UCB.
CB has been known to contain a population of
irculating cells that serve as progenitors for the en-
othelial lineage (EPCs). We have determined that a
are population of cells in the umbilical cord blood
merges upon in vitro culture that displays clonal
olony forming ability. These endothelial colony
orming cells (ECFCs) are present in adult peripheral
lood as well, though vastly enriched in term and
reterm cord blood. ECFCs spontaneously form hu-
an blood vessels upon implantation into immunode-
cient mice and participate as blood conduits. Recent
tudies indicate that ECFC can be derived from um-
ilical arterial and venous endothelial cells as well as
ndothelium from several other vascular sites. Thus,
uman CB ECFCs may be useful as a source of cells to
egenerate human vasculature in vivo.
Tsuneo A. Takahashi discussed progress in regen-
rative medicine using CB: MSC isolation, and induc-
ion to bone and cartilage. MSC can be isolated from
ord blood (CB-MSCs) and from chorionic villi of the
lacenta (PL-MSCs) using the explant culture
ethod. They may differentiate into osteogenic,
hondrogenic, and adipogenic cells. PL-MSCs were
nduced to chondrocytes in vitro and produced a large
mount of extracellular matrix of cartilage in vivo.
L-MSCs could repair the cartilage defect in the knee
f a nude rat. MSCs could also be isolated from fresh
B and these cells expanded well with differentiation
bility to chondrocytes and osteocytes. Thus, both
L-MSCs and CB-MSCs are potential allogeneic
tem cell sources for tissue engineering for bone and
artilage.
ESSION VII. THE GRAFT VERSUS TUMOR EFFECT
Dr. Michael Verneris discussed the impact of multi-
nit UCB transplantation on leukemia relapse. One of
he most common complications of transplantation is
eukemia relapse. Variables that impact relapse in-
lude patient characteristics, the conditioning regi-
en, HLA disparity, the type of graft, and graft ma-
ipulation. Cell dose has a signiﬁcant impact on speed
f neutrophil recovery, probability of engraftment,
he risk of TRM, survival, the inﬂuence of HLA dis-
arity, and access to transplantation. The rationale for
he use of multi-unit CB transplants is the hypothesis Ahat augmentation of the cell dose by the infusion of
wo partially HLA matched UCB units will speed
ematopoietic recovery, reduce TRM, and improve
urvival. Early studies showed that the time to engraft-
ent was shifted from 32 days to 23 days with the use
f double CBTs vs. historical controls using a single
CB. The mechanism by which two units enhance
ngraftment could be the augmentation of stem cell
ose although immunologic reactions. A study was
erformed of 126 patients with AML or ALL who
eceived either a single or double UCBT using my-
loablative conditioning. Seventy two patients re-
eived a single unit and 54 received a double UCBT.
atients received a double CBT if there was not a
ingle unit available with an adequate cell dose. The
otal infused TNC was 3.2  107/kg for the single
ord transplants and 3.5  107/kg for double CBTs
NS). Total CD34 was also similar but CD3 cell
ose was larger for the double CBTs (0.9 vs 1.3 
07/kg). Results indicated that the rates of sustained
eutrophil engraftment and TRM were similar be-
ween single and double CBTs. However, the inci-
ence of grade II-IV aGVHD was higher with double
BTs, although the incidence of grades III-IV
GVHD was not different. The incidence of cGVHD
as low and there was no difference between the two
roups. The incidence of relapse for patients in CR1
nd CR2 was higher for single UCB recipients than
or double and this was not inﬂuenced by the diagnosis
AML vs ALL). OS at 3 years was 72% for double
BTs and 47% for single (P  .16). Considering
atients who survived for at least 9 months, all of the
ouble UCBT patients were alive whereas there were
5 deaths among the single cord transplant patients (P
.01) and 13 of 15 events were from relapse. Con-
lusions are that double UCBT promotes engraftment
chieving rates comparable to single UCBT with ad-
quate cell doses; the risk of grades II-IV aGVHD is
igher after double UCBT (although there is no dif-
erence in risk of grades III-IV aGVHD); and the risk
f cGVHD is similar. There is a reduced risk of
elapse associated with double UCBT and this was not
riven by aGVHD. Patients in early disease status
CR1 and CR2) were the only ones to show beneﬁt.
Dr. Jeffrey Miller discussed a novel triple UCBT
trategy to promote natural killer (NK) cell immuno-
herapy using a fully ablative preparative regimen fol-
owed by a double UCBT in patients with refractory
ML. The strategy was that appropriately chosen
onors will enhance NK cell alloreactivity if they
xpand in vivo. The best strategy may be to combine
doptive transfer and in vivo expansion followed by
CT. A trial was conducted with 19 poor prognosis
ML patients. These patients had primary refractory
isease, relapsed disease not in CR after 1 or more
ycles of standard re-induction therapy, secondary
ML from MDS, relapsed AML  3 months after
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Summary of IUCBT Symposium 1391CT, and no active infections. Results indicated that
iller cell immunoglobulin-like receptor (KIR) ligand
ismatched donor correlated with achieving CR (5 of
9). CR patients had higher numbers of functional
K cells after haplo NK cell infusions. Triple UCB
trategy was developed using UCB derived NK cell 
ouble UCB transplant for patients with refractory
ML. Results indicated 9 of 10 patients engrafted; all
achieved CR at day 14; 4 of 9 engrafted from the NK
ell unit #1; 2 are alive and in CR at days 120 and
262; 3 had TRM without evidence of relapse and
ied on days 2, 62, and 67; and 5 relapses oc-
urred (all were in CR at engraftment). In conclusion,
ctivated NK cells may facilitate engraftment, strate-
ies to better promote NK cells in vivo may improve
linical results, and the DCBT distant from the NK
ell unit may not be needed. Better strategies to make
rimary AML targets susceptible to NK cell killing
re being studied.
Dr. Hans G. Klingemann discussed ex-vivo expan-
ion and mRNA transfection of CB derived natural
iller cells. NK cells are a third subset of lymphocytes
in addition to T-and B cells). They are independent
f V(D)J recombination and receptor, kill virus in-
ected and transformed cells without priming, have an
mportant regulatory function (INF- g and other cy-
okines), kill MHC class I negative cells, express in-
ibitory receptors speciﬁc for “self” MHC class I, and
xpress many different activating receptors. CB is used
ecause it is a universal source of NK-cells, it is rich in
K cell progenitors, and NK cells are believed to be
ore active than peripheral blood NK cells. A prob-
em is that there are only a limited numbers in a given
B unit. A study was designed to develop an opti-
ized expansion system for CB NK cells suitable for
linical application, to make expanded cord NK cells
arget speciﬁc by transfection of mRNA for a chimeric
ntigen receptor recognizing CD19. mRNA is advan-
ageous compared to cDNA transfection in that there
s no genomic integration (mRNA stays in cytosol),
here is more efﬁcient transfection, expression is
ighly uniform, expression can be controlled by
hanging amount of input mRNA, and cells can be
fﬁciently and simultaneously loaded with several dif-
erent transcripts. Results indicate augmented cyto-
oxicity of NK cells transfected with mRNA express-
ng scFV-CD19. This is an important step to make
K cells targeted to tumor cells.
ESSION VIII. GOVERNMENTAL AFFAIRS
Robert Baitty, representing the U.S. Department of
ealth and Human Services (HHS), Health Re-
ources and Services Administration (HRSA), Divi-
ion of Transplantation, Blood Stem Cell Transplan-
ation Program, presented an update on the C.W. Bill coung Cell Transplantation Program (the Program)
nd the National Cord Blood Inventory. The aims of
he Stem Cell Therapeutic and Research Act of 2005
re to increase the number of unrelated donor trans-
lants, increase the public inventory of high quality
BUs from diverse populations and increase the num-
er of CBUs available for research. The Act autho-
izes appropriations of $15 million/year for FY 2007-
010; funding is temporary until 150,000 CBUs are
btained. HRSA’s implementation approach is guided
y three principles: a single point of access for patients
nd physicians to all sources of blood stem cells, col-
ection of high-quality diverse CBU expeditiously, and
ollection of complete data on clinical outcomes of
ransplants. The National Cord Blood Inventory
NCBI) will be funded through one-time, 10-year
ontracts awarded competitively with HRSA funds for
3 years; funded cord blood banks must participate in
he Program for 10 years; and the NCBI CBUs
ust be available through the Program in perpetuity
or until they are no longer viable). Contracts for the
rst cohort of banks were awarded November 2, 2006,
o six banks (New York Blood Center, Duke Univer-
ity, MD Anderson, Puget Sound Blood Center, Uni-
ersity of Colorado, and StemCyte). About 10,500
BU are to be collected with ﬁrst year of funding for
he ﬁrst cohort and these are to be comprised of
63% racial and ethnic minorities. Request for Pro-
osals for a second cohort of banks was published
pril 12 with responses due May 15, 2007. HRSA will
old annual competitions for new cohorts of banks, as
unding permits. Infrastructure contracts include a
ontract for the stem cell therapeutic outcomes data-
ase, which was awarded September 15, 2006, to the
enter for International Blood and Marrow Trans-
lant Research; contracts for an Ofﬁce of Patient
dvocacy/Single Point of Access, Bone Marrow Co-
rdinating Center, and a Cord Blood Coordinating
enter, which were awarded September 25, 2006, to
he National Marrow Donor Program. An Advisory
ouncil on Blood Stem Cell Transplantation is being
stablished whose purpose is to consider and make
ecommendations to the Secretary of HHS on matters
elated to the Program. Ongoing work includes: com-
lete the transition from the former National Bone
arrow Donor Registry structure to C.W. Bill Young
ell Transplantation Program, launch a web site for
he Program (mid-Summer 2007), begin collection of
lood stem cell transplant outcomes data (mid-Sum-
er 2007), complete establishment of the Advisory
ouncil and convene its ﬁrst meeting, and future
ycles of funding for NCBI collections. Further, im-
lement the Related Cord Blood Donor Demonstra-
ion Project, revisit interim program requirements
ith Advisory Council and public input, and deﬁne
argets for composition of NCBI and the size and
omposition of adult donor registry in consultation
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Summary of IUCBT Symposium1392ith the Advisory Council. Finally, to encourage re-
earch in collaboration with other Federal agencies
nd the Advisory Council to improve transplant out-
omes, reﬁne approaches to CB transplants for adult
atients, better deﬁne CBU characteristics required
or good outcomes, improve reliability and compara-
ility of measures used in CBU selection, and to col-
ect and report data regarding new uses of stem cells
rom CBU and adult donors.
Dr. Dennis Confer discussed the development of
he National Cord Blood Center. The contracts for
he Single Point of Access/Ofﬁce of Patient Advocacy
OPA/SPA) and the Cord Blood Coordinating Center
ere awarded to the National Marrow Donor Program
NMDP). The contract for the Stem Cell Therapeutic
utcome Database was awarded to the CIBMTR.
he OPA/SPA provides a uniform, consolidated
earch report (all searches are submitted here), pro-
ides advocacy services for patients, implements a plan
o increase transplants, and facilitates access to trans-
lantation services for patients. The Cord Blood Co-
rdinating Center facilitates transplants of cord blood
rom NCBI banks and from other participating banks,
ollects standardized CBU information from the
anks and provides this to the OPA/SPA, and coordi-
ates search and distribution of CBUs. The Cord
lood Coordinating Center will also develop an inter-
ank technical proﬁciency program, support public
nd professional education and recruitment activities,
ollaborate with CBBs to make CBUs available for
esearch, improve operating efﬁciencies in collabora-
ion with the network, support contingency planning
or emergencies, and require transplant centers to
ubmit outcomes data to the SCTOD. The Center for
nternational Blood and Marrow Transplant Research
CIBMTR) represents an afﬁliation between the re-
earch programs of former IBMTR/ABMTR at the
edical College of Wisconsin and NMDP to support
linical research in hematopoietic cell transplantation
nd related ﬁelds. The CIBMTR as the SCTOD
ontractor must establish electronic data capture sys-
ems, collect data on all allogeneic transplants with a
ecipient or donor in the U.S, collect data on other wellular therapies, disseminate data within the pro-
ram, make transplant data publicly available, perform
nalyses of optimal size for the adult donor registry
nd cord blood unit inventory, and conduct and sup-
ort research. In summary, the C.W. Bill Young
ransplantation Program provides a blueprint for or-
anizing and managing of unrelated donor hemato-
oietic cell transplantation, and establishes a clear
mphasis on Cord Blood as an important source of
ematopoietic and non-hematopoietic cells for treat-
ent of disease.
Dr. Ellen Lazarus, representing the FDA, Ofﬁce of
ellular, Tissue and Gene Therapies, Division of Hu-
an Tissues, presented an update on FDA Regulatory
ctivities for Cord Blood. A draft guidance was pub-
ished January 16, 2007, and represents FDA’s current
hinking but does not establish legally enforceable
esponsibilities. Its purpose is to recommend ways for
ord blood banks to apply for licensure for speciﬁed
ndications, to explain applicable regulations in Title
1 of the Code of Federal Regulations, and to provide
ther information about the manufacture of human
ord blood progenitor cells (HPC-C) and how to
omply with the applicable regulatory requirements.
he Guidance may be used when applying for a bio-
ogics license. The FDA will review the application,
chedule a prelicense inspection as soon as possible
fter receiving the complete application, and if the
pplication is not complete, will identify and advise
he establishment of additional information that they
ill need to submit. The Draft Guidance Sections
nclude factors of signiﬁcance include HPC-C de-
cription and characterization, manufacturer informa-
ion, methods of manufacturing, and other informa-
ion. Applicable regulations and post-marketing
ctivities include applicable CGTPs and CGMPs and
linical outcome data collection. An Advisory Com-
ittee meeting was held on 4/30/07, at which CB
ssues under consideration were addressed. The next
teps area will be reviewing comments to the docket
nd recommendations of the Advisory Committee,
nd ﬁnalization of the Guidance. License applications
ill be accepted at any time.
